Evidence map›Paper›PMID 39148837›Full record

ArticlemedRxiv : the preprint server for health sciences2024

Dynamic and prognostic proteomic associations with FEV

Lisa Ruvuna, Kahkeshan Hijazi, Daniel E Guzman, Claire Guo, Joseph Loureiro, Edward Khokhlovich, Melody Morris, Ma'en Obeidat, Katherine A Pratte, Katarina M DiLillo and 29 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

39 authors.

Lisa RuvunaPulmonary Sciences and Critical Care Medicine University of Colorado Denver, Colorado.
Kahkeshan HijaziNovartis Institute of Biomedical Research, Cambridge, MA, United States.
Daniel E GuzmanColumbia University Irving Medical Center, New York Presbyterian, New York, NY, United States.
Claire GuoNational Jewish Health, Denver, CO, United States.
Joseph LoureiroNovartis Institute of Biomedical Research, Cambridge, MA, United States.
Edward KhokhlovichNovartis Institute of Biomedical Research, Cambridge, MA, United States.
Melody MorrisNovartis Institute of Biomedical Research, Cambridge, MA, United States.
Ma'en ObeidatNovartis Institute of Biomedical Research, Cambridge, MA, United States.
Katherine A PratteNational Jewish Health, Denver, CO, United States.
Katarina M DiLilloBiomedical Engineering, University of Michigan, Ann Arbor, MI, United States.
Sunita SharmaPulmonary Sciences and Critical Care Medicine University of Colorado Denver, Colorado.
Katerina KechrisDepartment of Biostatics and Informatics, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
Antonio AnzuetoUniversity of Texas Health Science Center and South Texas Veterans Health Care System, San Antonio, Texas.
Igor BarjaktarevicDavid Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.
Eugene R BleeckerMayo Clinic School of Medicine - Scottsdale Campus Scottsdale, AZ, US.
Richard CasaburiLundquist Institute for Biomedical Innovation at Harbor-University of California Los Angeles Medical Center, Torrance, California.
Alejandro ComellasCarver College of Medicine, University of Iowa, Iowa City, Iowa.
Christopher B CooperDavid Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.
Dawn L DeMeoChanning Division of Network Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
Marilyn ForemanPulmonary and Critical Care Medicine Division, Morehouse School of Medicine, Atlanta, GA.
Eric L FlenaughPulmonary and Critical Care Medicine Division, Morehouse School of Medicine, Atlanta, GA.
MeiLan K HanDivision of Pulmonary and Critical Care Medicine, University of Michigan Health System, Ann Arbor, Michigan.
Nicola A HananiaSection of Pulmonary and Critical Care Medicine, Baylor College of Medicine, Houston, TX.
Craig P HershChanning Division of Network Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
Jerry A KrishnanBreathe Chicago Center, Division of Pulmonary and Critical Care Medicine, University of Illinois at Chicago College of Medicine, Chicago, Illinois.
Wassim W LabakiDivision of Pulmonary and Critical Care Medicine, University of Michigan Health System, Ann Arbor, Michigan.
Fernando J MartinezDepartment of Medicine, Weill Cornell Medical College, New York-Presbyterian Hospital/Weill Cornell Medical Center, New York, New York.
Wanda K O'NealMarsico Lung Institute, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Robert PaineDivision of Respiratory, Critical Care and Occupational Medicine, University of Utah, Salt Lake City, Utah, United States.
Stephen P PetersDepartment of Internal Medicine, Center for Precision Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina.
Prescott G WoodruffDivision of Pulmonary Critical Care, Allergy, and Sleep Medicine, University of California San Francisco, San Francisco, California, United States.
J Michael WellsLung Health Center, University of Alabama at Birmingham, Birmingham, Alabama.
Christine H WendtMinneapolis VA Health Care System, Minneapolis, Minnesota.
Kelly B ArnoldBiomedical Engineering, University of Michigan, Ann Arbor, MI, United States.
R Graham BarrColumbia University Irving Medical Center, New York Presbyterian, New York, NY, United States.
Jeffrey L CurtisDivision of Pulmonary and Critical Care Medicine, University of Michigan Health System, Ann Arbor, Michigan.
Debby NgoNovartis Institute of Biomedical Research, Cambridge, MA, United States.
Russell P BowlerGenomic Medicine Institute, Cleveland Clinic, Cleveland, OH, United States.
SPIROMICS, COPDGene and MESA-Lung Investigators

Funding

Institute for Clinical and Translational ResearchUL1TR001079 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2013 to 2017
$60.1M
Genetic Epidemiology of COPDU01HL089897 · NHLBI · NATIONAL JEWISH HEALTH · PI CRAPO, JAMES D · 2007 to 2021
$56.9M
Pulmonary Toxicology Facility CoreP30ES005605 · NIEHS · UNIVERSITY OF IOWA · PI Jong Sung Kim · 1990 to 2026
$40.5M
Wake Forest Clinical and Translational Science AwardUL1TR001420 · NCATS · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI ARD, JAMY D, FOLEY, KRISTIE L · 2015 to 2023
$32.3M
SPIROMICS II: Biological underpinnings of COPD heterogeneity and progressionU01HL137880 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WOODRUFF, PRESCOTT G · 2017 to 2021
$27.9M
Clinical and Translational Science AwardUL1TR000040 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GINSBERG, HENRY N · 2012 to 2015
$26.2M
Genetic Epidemiology of COPDU01HL089856 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI SILVERMAN, EDWIN K · 2007 to 2021
$20.7M
Pulmonary microvascular perfusion in the Multi-Ethnic Study of AtherosclerosisR01HL077612 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI R Graham BARR · 2004 to 2026
$18.8M
Pulmonary Vascular Changes in Early Chronic Obstructive Pulmonary Disease (COPD)R01HL093081 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI R Graham BARR · 2008 to 2026
$17.2M
Task Area A Core Study Operations.Task Area A shall encompass annual follow-up of cohort members, clinical endpoints ascertainment, study coordination activities, maintenance of the database and biosp75N92020D00001 · NHLBI · UNIVERSITY OF WASHINGTON · PI MCCLELLAND, ROBYN LEAGH · 2020 to 2025
$17.2M
Understanding the Origins of Early COPDR01HL144718 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · PI CURTIS, JEFFREY LOUIS, HAN, MEILAN K · 2020 to 2024
$11.3M
SPIROMICS GIC SupportU24HL141762 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI COUPER, DAVID J, O'NEAL, WANDA K · 2018 to 2022
$7.2M
NCATS NIH HHS UL1 TR000040NCATS NIH HHS UL1 TR001079NCATS NIH HHS UL1 TR001420NHLBI NIH HHS 75N92020D00001NHLBI NIH HHS 75N92020D00002NHLBI NIH HHS 75N92020D00003NHLBI NIH HHS 75N92020D00004NHLBI NIH HHS 75N92020D00005NHLBI NIH HHS 75N92020D00006NHLBI NIH HHS 75N92020D00007NHLBI NIH HHS HHSN268200900013CNHLBI NIH HHS HHSN268200900014CNHLBI NIH HHS HHSN268200900015CNHLBI NIH HHS HHSN268200900016CNHLBI NIH HHS HHSN268200900017CNHLBI NIH HHS HHSN268200900018CNHLBI NIH HHS HHSN268200900019CNHLBI NIH HHS HHSN268200900020CNHLBI NIH HHS HHSN268201500003CNHLBI NIH HHS HHSN268201500003INHLBI NIH HHS N01 HC095159NHLBI NIH HHS N01 HC095160NHLBI NIH HHS N01 HC095161NHLBI NIH HHS N01 HC095162NHLBI NIH HHS N01 HC095163NHLBI NIH HHS N01 HC095164NHLBI NIH HHS N01 HC095165NHLBI NIH HHS N01 HC095166NHLBI NIH HHS N01 HC095167NHLBI NIH HHS N01 HC095168NHLBI NIH HHS N01 HC095169NHLBI NIH HHS R01 HL077612NHLBI NIH HHS R01 HL093081NHLBI NIH HHS R01 HL130506NHLBI NIH HHS R01 HL137995NHLBI NIH HHS R01 HL144718NHLBI NIH HHS T32 HL144442NHLBI NIH HHS U01 HL089856NHLBI NIH HHS U01 HL089897NHLBI NIH HHS U01 HL137880NHLBI NIH HHS U24 HL141762NIEHS NIH HHS P30 ES005605
6 · The paper itself

Abstract

Rationale: Identification and validation of circulating biomarkers for lung function decline in COPD remains an unmet need. Objective: Identify prognostic and dynamic plasma protein biomarkers of COPD progression. Methods: We measured plasma proteins using SomaScan from two COPD-enriched cohorts, the Subpopulations and Intermediate Outcomes Measures in COPD Study (SPIROMICS) and Genetic Epidemiology of COPD (COPDGene), and one population-based cohort, Multi-Ethnic Study of Atherosclerosis (MESA) Lung. Using SPIROMICS as a discovery cohort, linear mixed models identified baseline proteins that predicted future change in FEV Measurements and Main Results: The prognostic model found 7 significant proteins in common (p < 0.05) among all 3 cohorts. After applying false discovery rate (adjusted p < 0.2), leptin remained significant in all three cohorts and growth hormone receptor remained significant in the two COPD cohorts. Elevated baseline levels of leptin and growth hormone receptor were associated with slower rate of decline in FEV Conclusion: We identified leptin as the most reproducible COPD progression biomarker. The difference between prognostic and dynamic proteins suggests disease activity signatures may be different from prognosis signatures.

Indexed as

Disease ProgressionProteomicsSpirometry

Identifiers

PMID39148837
PMCPMC11326337

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.